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Idiopathic intracranial hypertension (IIH) is a disorder which is not that unusual 
for neurologists and ophthalmologists to meet in clinical practice even though it 
only affects around 1 per 100,000 individuals. It gives rise to symptoms of head-
ache and visual disturbances caused by high intracranial pressure (ICP). The first 
recorded patient with this disorder was described by Quicke in 1893, followed 
by 22 cases reported by Dandy in 1937, who later summarized the common diag-
nostic characteristics of the disorder (1). Even though we have known about this 
disorder for far more than 100 years and several studies have been performed to 
investigate its origin, we still don’t know what causes the increased pressure. We 
know that it more commonly affects females of reproductive age, in particular 
those who are obese. But why this is the case is not known. Several hypotheses 
have been suggested and studied over the years. Additionally, several risk factors 
that could be involved in the development of high intracranial pressure have been 
proposed. However, since the disorder and some of its risk factors are rare, there 
have been conflicting findings as to the strength of some of the proposed associa-
tions between such risk factors and IIH development. 
The intension of this thesis was to conduct studies investigating the incidence of 
IIH in Sweden as well as describing a Swedish cohort to shed light onto potential 
different risk factors. We used Swedish large national registers to investigate if risk 
factors were more common in IIH cases compared to controls prior to diagnosis. 
Study I is a descriptive study of all patients with a diagnosis code for IIH in 
Stockholm County during 2006-2013.We included 207 individuals ≥18 years of 
age with the diagnosis code G93.2 registered in the national patient register during 
these years. We validated the diagnosis coding by review of medical records and 
found that only 65% fulfilled the modified Dandy diagnostic criteria for IIH. The 
incidence was 0.65 per 100,000 individuals, in the lower range of most reported 
incidence studies on IIH. Among those fulfilling IIH diagnosis criteria, as reported 
in other studies, most patients were females (F/M ratio of 6:1) and females were 
slightly younger than men at time of diagnosis (mean age women 31 (CI 29-33) 
compared to 43 (CI 36-50) in men). 
These results provided the motivation to improve finding correctly diagnosed IIH 
patients to include in register studies. In study II we therefore developed algorithms, 
that included parameters thought to improve prediction by using data which are 
possible to extract from registers, to better predict which patients to include as 
“true” IIH cases. We developed the algorithms by testing these parameters using a 
stepwise logistic regression model on a randomized one half of study I individuals 
and then tested how well they predicted on the other half. By using parameters age, 
receiving 3 or more registrations of the diagnosis code G93.2, and in the second 
algorithm also adding acetazolamide treatment (needing use of drug register data) 
prediction of true cases improved to 86% and 88%, respectively.
With use of the developed algorithms we continued to do the national case-control 
register studies looking at exposure to risk factors in the year prior to the first IIH 
diagnosis to undertake study III and IV. We looked at the whole population over 
18 years during 2000-2016. In study III and IV 902 IIH cases and 4510 matched 
general population (GP) controls and 4510 obese controls were included. Matching 
factors were age, sex, and region of residence at the time the IIH patient in the 
matched group was diagnosed. When analyzing drug dispensations, we had 654 
IIH cases and 3270 corresponding GP and obese controls, respectively included. 
In study I, we found that conditions causing an inflammatory response were com-
mon. In study III we therefore wanted to analyze this in a larger population. The 
results from study III showed increased OR for both infectious (OR = 4.3; 95% CI 
3.3-5.6) and inflammatory disorders (OR = 3.2; 95% CI 2.4-4.3) the year prior to 
the first IIH diagnosis compared to GP controls. Similarly, OR were significantly 
increased though of slightly lower magnitude compared to the obese controls. 
In Study IV we investigated the incidence of IIH in Sweden and evaluated risk 
factors previously proposed in the literature. The mean incidence in the adult popu-
lation over the study period was similar to study I; 0.71 per 100,000 individuals. 
The incidence showed however a steady increase which we believe is related to 
increasing obesity worldwide, as well as in Sweden. Regarding risk factors we 
could conclude that we saw a significant increased risk of exposure to several 
disorders, especially kidney failure, SLE, PCOS, tetracyclines, and lithium and 
systemic corticosteroid treatments. We also found surprisingly high OR for arterial 
hypertension which in recent years has not been considered a risk factor although 
it has been described. Equally important, our results confirm that hormonal con-
traceptives and pregnancy are not likely to be risk factors for IIH. In this study 
and this thesis, we discuss common denominators regarding risk factors for IIH 
and proposed three main hypotheses; an inflammation theory, an androgen theory 
and an ICP regulatory mechanism theory to be of interest for further research.
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Idiopathic intracranial hypertension (IIH) is an uncommon disorder with symp-
toms caused by elevated intracranial pressure (ICP) of unknown cause. It mainly 
affects obese women of childbearing age (2). The symptoms include headache, 
visual disturbances (vision field defects, acuity or double vision), pulsatile  tinnitus, 
and nausea.
1.1 Terminology and clinical diagnosis
The disorder IIH has over the years been described with different terms; pseudo-
tumor cerebri syndrome, benign intracranial hypertension, but in recent years 
idiopathic intracranial hypertension is the most frequently used term. The first 
description of the syndrome with a presentation of various cases was published 
by Dandy in 1937 (1). The diagnostic criteria mainly used over the years for IIH 
diagnosis was formulated by Smith in 1985, the so called modified Dandy Criteria 
(3), see table 1.
Table 1. Diagnostic criteria for IIH – the modified Dandy Criteria (3, 4)
The modified Dandy Criteria
1. Signs and symptoms of increased intracranial pressure (headaches, nausea, vomiting, 
transient obscurations of vision, papilledema).
2. No localizing neurologic signs otherwise, with the single exception being unilateral or 
bilateral VI nerve paresis.
3. CSF can show increased pressure, but no cytologic or chemical abnormalities 
otherwise.
4. No evidence of hydrocephalus, mass, structural, or vascular lesion on MRI or 
 contrast-enhanced CT for typical patients, and MRI and MR venography for all others.
Abbreviations: CSF, cerebrospinal fluid; CT, computed tomography; MRI, magnetic resonance 
imaging.
However, new criteria for this syndrome as well as a new name for this disorder 
was proposed by Friedman et al (5). The name pseudotumor cerebri syndrome 
was then reused and the criteria subdivided the disorder into primary pseudotumor 
cerebri syndrome (primary PTCS) and secondary pseudotumor cerebri syndrome 
(secondary PTCS). Primary PTCS was proposed to comprise traditional IIH criteria 
with a typical clinical picture and no associated risk factors apart from obesity, 
recent weight gain, and poly-cystic ovarian syndrome (PCOS). Secondary PTCS 
was proposed to include patients with underlaying disorders such as cerebral 
venous trombosis, as well as a syndrome clinically similar to primary PTCS but 
in association with certain risk factors (various comorbidities and medications 
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further specified in chapter 1.4 on risk factors and in table 3 and 4)). Friedman 
also divided the syndrome into pseudotumor cerebri with or without papilledema. 
Friedman’s criteria are not universally accepted, and many studies still use the old 
modified Dandy Criteria which we also chose to do. 
There are some recent data on typical radiological findings (5) in IIH and it has 
been suggested that improved magnetic resonance imaging (MRI) diagnostics 
should be used when setting the diagnosis, especially in uncertain cases. For 
example, the new proposed criteria involve MRI criteria for diagnosis in  probable 
cases (5) and suggests the following radiological diagnostics to be used in the 
investigation for IIH:
• MRI with and without gadolinium enhancement
• MRI venography for atypical patients
• If MRI is contraindicated contrast-enhanced computer tomography (CT)
• If the patient does not have papilledema or six nerve palsy indicating long-
standing increase intracranial pressure (ICP), then signs of high ICP should be 
evident on MRI to set a final diagnosis (5), see table 2. 
Table 2. Signs/findings on MRI indicating high intracranial pressure (5)
MRI findings of high ICP should include at least three of the following:
i. Empty sella 
ii. Flattening of the posterior aspect of the eye bulb 
iii. Distention of the perioptic subarachnoid space with or without a tortuous optic nerve
iv. Transverse venous sinus stenosis.
It is important to bear in mind however that these radiological findings are not 
specific for IIH and lack of them does not exclude high ICP. For example, empty 
sella (i.e. the pituitary gland is flattened and sella turcica filled with cerebrospinal 
fluid instead of gland material) has sensitivity (80%) and specificity (83%) therefore 
being commonly seen also in normal persons (6). Sinus stenosis on gadolinium 
enhanced MRI however has both high sensitivity and specificity (>93%)(6, 7).
1.2 Epidemiology of IIH
1.2.1 Age distribution, sex, and socioeconomic factors
IIH usually affects patients in the age of 15 to 45 years (8, 9). A large proportion 
of those affected are overweight/obese, or have a recent weight gain (10). It is 
also more common among females (approximately nine times more frequent in 
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females than males) in this age group (15-45) (11). IIH is also seen in the pedi-
atric population, however prior to reaching adolescent age, the association with 
female sex and obesity is not present (12). The disorder is also shown to greatly 
affect patients’ lives, their families, and impact on society. For example, it has 
been shown that the IIH disorder causes loss of income for patients, substantial 
health-care costs for society (13, 14) and high emergency department utilization 
(15). IIH also has negative effects on quality of life (16-18). Some studies have 
also shown an association to cognitive dysfunction in IIH patients (19, 20); these 
studies described cognitive dysfunction most noted in the domains visual spatial, 
global cognitive score, reaction time, and processing speed compared to normal 
controls. These are factors that may indirectly affect income and sick leave com-
pensations with consequences to both the individual and the society. 
1.2.2 Incidence and prevalence
The yearly incidence of IIH has been described within a wide range in different 
regions of the world varying between 0.03-4.7 per 100,000 (14, 21). In a recent 
metanalysis the pooled incidence of IIH was 1.2 per 100,000. Large studies per-
formed in USA, Libya, Israel, Northern Ireland, Scotland and England report 
incidences between 0.9 and 4.7 per 100,000 individuals (8, 14, 22-26). There are 
however also reports of much lower incidence; for example in a relatively large 
cohort in Japan the incidence was only 0.03 per 100,000 (21) and in Italy (Parma) 
0.3 per 100,000 inhabitants (27). Several studies speculated that the differences 
seen in incidence in these studies to a large extent could be due to differences in 
obesity prevalence, but other factors (e.g. genetic) could play an important role 
as well. Rising incidence of IIH in several regions has been reported (14, 23-26, 
28) and has been proposed to be correlated to the increase in obesity prevalence. 
The incidence of IIH in a Scandinavian population has never been investigated.
Prevalence is less commonly reported but studies in England and Ireland have 
calculated the prevalence during the respective study period to be 10.9-14.3 per 
100,000 inhabitants (23, 28).
1.2.3 Register data on IIH
A correct (diagnosis) coding of IIH in registries has been shown to be low. Fisayo 
(29) showed that 40 percent with an initial diagnosis of IIH got a changed diag-
nosis on follow up visit. Koerner et al (30) only found a positive predictive value 
(PPV) of 55% when they evaluated all diagnoses given in inpatient and emergency 
hospital settings. Also, a correct diagnosis of IIH can be associated with difficul-
ties due to ophthalmological misinterpretation of a proposed papilledema (29). 
Increased intracranial pressure can also be misinterpreted if measured incorrectly 
or if the patient is not relaxed during the lumbal puncture procedure. 
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1.3 Pathophysiology
The pathophysiology of IIH is largely unknown even though there are several 
theories suggesting various mechanisms that could be involved. As the skull 
represents a rigid volume space this means that disorders causing high ICP must 
originate from increased amount of some of the brain constituents such as the 
cerebrospinal fluid (CSF), the interstitial fluid (ISF), the blood, or the brain cells. 
The basic principle to explain the intracranial pressure physiology is the Monroe-
Kellie Doctrine, see figure 1. In neurointensive care we have primarily focused 
on ICP in relation to the arterial blood pressure, measuring mean arterial pressure 
(MAP), cerebral perfusion pressure (CPP) and ICP. But changes in vascular pres-
sure on the venous side might be more important as ICP regulatory mechanisms 
as there is less resistance compared to on the arterial side (31). Cerebral blood 
both in and outflow seems to be important when regulating ICP but other factors 
affecting other brain constituents might also be involved in the pathogenesis of 
IIH causing impaired ICP homeostasis (32). 
Figure 1. The Monroe-Kellie doctrine (31).














1.3.1 Increased CSF production
The average human produces approximately 600ml of CSF per day (the majority 
from the choroidal epithelium, and < 10% from ISF) which is about three to four 
times the total CSF volume (33). The production of CSF is shown to reduce with 
age (33) which may be an explanation why IIH only affects younger to middle 
aged persons. It has been shown that CSF production is relatively independent 
of ICP (34). 
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1.3.1.1 Aquaporins
Aquaporins (AQP) are water permeable channels in the central nervous system 
(CNS) that facilitate water movement across cell membranes in supporting cells 
of the CNS. Nine different kinds have been described and two of them have been 
especially interesting regarding IIH. AQP1 is expressed in the choroid plexus cells 
and thought to be involved in the production of CSF. AQP4 is mainly expressed 
in glial cells throughout the brain and spinal cord and is responsible for much of 
the water flow in and out of the brain over the blood brain barrier (BBB) and the 
blood-CSF barrier (35). Interestingly acetazolamide (which is used as first line 
treatment regime for IIH) has been shown to inhibit AQP4 activity (36) and modu-
late AQP1 activity (37). Eide et al (38) have shown histopathological alterations 
with cortical patchy astrogliosis in combination with AQP4 being increasingly 
expressed in the brain of IIH patients undergoing shunt procedures. As opposed 
to this study, one genetic study sequencing the gene AQP4 on chromosome 18 
did not find any difference between 28 IIH patients compared with controls (39). 
Another negative study measured serum neural and glial antibodies but did not 
find any antibodies against AQP4 in IIH patients (40).
1.3.2 Decreased CSF absorption
CSF is absorbed by transportation to the subarachnoidal space where the major-
ity is absorbed to a large extent by the arachnoid granulations/arachnoid villi in 
the sagital sinus. Previously it was thought that all CSF was absorbed this way, 
but in recent years evidence points towards CSF being absorbed in several parts 
of the CNS. Edsbagge et al showed that up to 50% of CSF may be absorbed by 
spinally located arachnoid villi (41). It has also been shown that CSF is likely to 
be absorbed into the lymphatic system, probably primarily through the cribriform 
plate where olfactory nerves pass as well as CSF sheath and dura (42). It has 
also been shown that persons with IIH more commonly also have problems with 
hyposmia (ability to smell/detect odors) (43-45). It has been speculated that this 
pathway (through the cribriform plate) of CSF absorption might be important. 
There is also some evidence in CSF infusion studies for increased resistance of 
CSF absorption in IIH patients (46, 47). 
1.3.3 Increased central venous pressure and outflow resistance
Hypotheses have over the years discussed a possible pathophysiological mechanism 
with increased central venous pressure as an explanation behind increased ICP 
in IIH patients (7, 48-50). Different aspects have been proposed to be important 
in ICP regulations with aspects from the venous system both intra- and extra-
cranially in general both regarding IIH and other disorders causing intracranial 
hypertension (31), see figure 2. Central (abdominal) obesity is proposed causing 
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increased intra-abdominal pressure that via raised pleural pressure and cardiac 
filling pressure would impair venous blood return and cause increased venous 
pressure in the CNS (48, 51). An association with jugular valve impairment has 
also been demonstrated in IIH patients possibly contributing to this phenomenon 
(49). Resistance to venous outflow by stenosis of the venous sinuses (7) has also 
been shown to be common in IIH patients. 
Figure 2. Venous outflow restrictions that can affect ICP (31).
Showing potential venous outflow restrictions that can affect ICP both intracranially 
(obstruction/compression) or extracranially (cervical, thoracic and abdominal pressure). 
Figure originally published by Mark Wilson in J of Cerebral Blood Flow & Metabolism 
2016, volume 36, issue 8, p1338-50. Published with permission according to Creative 
Commons license; https://creativecommons.org/licenses/by-nc/3.0/
1.3.3.1 The venous sinuses
In recent years a lot of focus has been towards resistance to venous outflow by 
stenosis in the transverse sinus. Farb et al (7) showed that bilateral venous sinus 
stenosis is common in IIH patients. They observed this phenomenon in 27 out 
of 29 IIH patients but only 4 out of 59 control patients. It is debated whether the 
stenosis seen is a cause or a consequence of high ICP. It has been suggested that 
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the stenosis is caused by a collapse of the sinus walls due to the high ICP. Some 
studies have shown the stenosis to resolve with intensive treatment and normali-
zation of the ICP by CSF diversion procedures (52, 53), while other studies have 
not (despite a normalization of the ICP under a longer time span with medical 
treatment – the stenosis still remained (54)). It’s increasingly recognized that the 
stenosis is symptomatic and could benefit from treatment. Surgical treatment 
with venous sinus stenting is described in the literature where expansion of the 
compressed area with a stent was shown to be favorable in patients with IIH not 
responding to medical treatment or to cases with fulminant IIH with acute progress 
of symptoms (55-57). 
1.4 Risk factors
There are many factors proposed to be associated with IIH (58, 59). However, 
evidence for a true association for many of these risk factors are lacking as most 
studies are based on small case-control studies (involving 20-60 cases) (60-64) 
or case reports that do not have enough sample size to draw strong conclusions. 
Only one recent case-control study exploring cycline antibiotics in association to 
IIH included as many as 339 IIH cases (65). Suggested risk factors need verifica-
tion compared to what would be expected as “normal /coincidental” exposure in 
large case-control studies. 
1.4.1 Female predominance
Female sex is highly associated with an increased risk of IIH after puberty (11, 
60). Only 8-19% of the IIH cases are male (11). Factors that cause this sex differ-
ence are unknown. Female predominance after puberty suggests that hormones 
play an important part in the development of IIH, however studies have not been 
able to prove this relationship (66).
1.4.1.1 Suggested androgen theory
It has been proposed that increased testosterone levels in women and lower testos-
terone levels in males could be a risk factor for IIH (67). In support of this theory 
female IIH patients seem to have a different androgen endocrine profile compared 
to both obese female controls with polycystic ovary syndrome (PCOS) and obese 
female controls without PCOS (68). This previous study showed a statistically 
significant difference with increased serum testosterone levels and CSF androgen 
levels in female IIH patients compared with controls. PCOS is known to be associ-
ated to hyperandrogenism and has been reported to be a risk factor associated with 
IIH and to obesity(69). It has also been shown that males with IIH seem to have a 
higher risk than controls for having signs of testosterone deficiency (61). A case 
study describes development of secondary IIH in a man with prostate cancer and 
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previous anti-androgen treatment in combination with weight gain (70). In women 
hyperandrogenism has been described as associated with earlier onset of IIH (71). 
There are also several case reports of females and males that during transsexual 
treatments have developed IIH (72-75). Yet another study showed an association 
to visceral obesity and androgens with a similar pattern as described above (low 
androgen/testosterone levels in males and high levels in females) (76). These stud-
ies propose evidence of androgens playing a role in IIH development.
1.4.2 Obesity
There is a lot of evidence that obesity is very highly associated with IIH (17, 58, 
60, 62, 77), and it is believed to be the most common risk factor for IIH develop-
ment. The majority of IIH patients are overweight or obese (10). The risk increases 
in relation to Body Mass Index (BMI) (17). Additionally, in patients with a BMI 
<30 kg/m2, recent weight gain is shown to be common before development of IIH 
disorder (17, 77). Weight gain is also associated with recurrence of the disorder 
(77) and weight loss is shown to improve symptoms of IIH (78-81). However how 
obesity interacts with IIH is incompletely understood. As presented before (see 
section 1.3.3) there have been theoretical hypotheses that abdominal obesity in IIH 
patients causes increased intra-abdominal pressure, which is a possible explanation 
for the high intracranial pressure in IIH (48). This hypothesis is challenged, however, 
since most obese persons with abdominal obesity do not develop IIH. Distribution 
of fat tissue might also be of importance. The findings of a small cohort study found 
significantly lower waist-to-hip ratio in IIH patients compared with obese controls 
(82). The effect of obesity on IIH risk could possibly also have an the association 
with androgen theory described above (76).  
1.4.2.1 Cytokines and chemokines
The adipose tissue is known to be a neuroendocrine organ secreting many biological 
factors which result in a pro-inflammatory state (83, 84). This has been speculated 
as an explanation behind IIH pathophysiology. Altered serum or CSF levels of cer-
tain cytokines and chemokines have been demonstrated, but there have also been 
conflicting results, with some studies showing significant differences (85-88) and 
other not (89). Leptin has been of interest, but results are conflicting. Some studies 
have shown significantly higher levels of leptin compared with controls (86, 89, 
90) suggesting a hypothalamic leptin resistance impairing appetite control (89) and 
it has been suggested that central leptin resistance could have a role in epithelial 
choroidal plexus cells causing increased CSF secretion (32). 
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1.4.2.2	 Glucocorticosteroids	and	11β-HSD1
Glucocorticoid withdrawal as well as Cushing’s and Addison’s disease have 
been proposed to be associated with IIH development pointing towards some 
association between corticosteroids and IIH (91-93). Previously corticosteroids 
were used in the treatment for IIH but are nowadays not recommended due to 
side effects, especially weight gain, no evidence of a sustained effect, and a risk 
of worsening when tapering the treatment (94). The enzyme 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1) has been demonstrated to be dysregulated in 
obesity (95). The pathophysiological explanations in IIH suggests that cytokines 
expressed in the obese activate 11β-HSD1. As a result, increased levels of 11β-
HSD1 in IIH patients cause activation of cortisone to cortisol, which might affect 
ICP. The proposed mechanism for this is through the effect on the choroid plexus 
cells ( possibly through effect on the Na+-K+-ATPase pump) and on arachnoid 
granulation cells thereby causing CSF dysregulation by means of increased CSF 
production and decreased CSF absorption (32, 96, 97). Furthermore, 11β-HSD1 
activity has been shown to be reduced after introduction of a low-calorie diet with 
weight loss in IIH patients (96), which could be an important factor explaining the 
improvement of ICP after weight loss in IIH patients. A new treatment is  currently 
being investigated for IIH using 11β-HSD1 inhibitor (phase II study) (98). 
1.4.3 Other proposed associated comorbidities 
There are several comorbidities that over the years have been associated with 
IIH. For some comorbidities the level of evidence is higher than for others. 
Comorbidities described as highly associated with IIH are for example Addison’s 
disease, hypoparathyroidism, and hypervitaminosis A (58). The recently pro-
posed Friedman criteria for the diagnosis suggest that presence of any of these 
risk factors (comorbidities and medications) should alter the diagnosis from IIH 
to secondary pseudotumor cerebri syndrome (5). On the other hand since many 
of these comorbidities have not been proven truly associated with IIH as pointed 
out by Chen et al (58) further studies are recommended. Many risk factors in their 
review were categorized as “possible risk factors” such as iron deficiency anemia, 
obstructive sleep apnea syndrome or “probable risk factors” such as uremia. Those 
risk factors are also included as causing secondary pseudotumor cerebri in the 
new proposed criteria. See table 3 for risk factors causing secondary pseudotumor 
cerebri syndrome in the new proposed criteria (5). Prior to the studies included in 
this thesis, large scale studies comparing these risk factors with the prevalence in 
a control population were lacking.
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Table 3. Comorbidities proposed to cause secondary pseudotumor cerebri  syndrome (5)
Cerebral venous abnormalities: Medical conditions:
Cerebral venous sinus thrombosis Endocrine disorders:
 Addison’s disease
 Hypoparathyroidism
Bilateral jugular vein thrombosis or surgical ligation Hypercapnia:
 Sleep apnea syndrome
 Pickwickian syndrome
Middle ear or mastoid infection Anemia
Increased right heart pressure Renal failure
Superior vena cava syndrome Turner’s syndrome
Arteriovenous fistulas Down’s syndrome
Decreased CSF absorption from previous intracranial 
 infection or subarachnoid hemorrhage
Hypercoagulable states
1.4.4 Medications proposed as being associated with IIH
Medications strongly associated with IIH are substances containing retinoid and 
tetracycline derivatives, growth hormone used in children and steroid withdrawal. 
Also other medications with less strong evidence have been described as being 
associated with IIH, such as lithium, corticosteroids, and sulpha antibiotics among 
others (58). Regarding association with medications the new proposed criteria by 
Friedman also suggest most of the above-mentioned drugs are likely a cause of 
secondary pseudotumor cerebri (5). See table 4 for medications and exposures 
causing secondary pseudotumor cerebri syndrome in the new proposed criteria (5). 




 Tetracycline, minocycline, doxycycline, nalidixic acid, sulpha drugs 
Vitamin A and retinoids:
 Hypervitaminosis A, isotretinoin, all-trans retinoic acid for promyelocytic leukemia, 
excessive liver ingestion
Hormones:
 Human growth hormone, thyroxine (in children), leuprorelin acetate, levonorgestrel 
(Norplant system), anabolic steroids




1.5 Adverse health outcomes
IIH is a disorder that often causes symptoms of longstanding headache and visual 
deficits. In a Danish study by Yri et al some 40% had remaining headache fulfill-
ing criteria for chronic headache one year after diagnosis (99). Permanent visual 
damage has been shown to be common. Around 40% of patients improve without 
visual symptoms, with most patients experiencing generally minor visual field 
defects, however 5-10% are at risk of obtaining more severe permanent visual 
defects, including blindness (3, 100). Cognitive dysfunction is also described 
among patients with IIH (19, 20) as well as decreased quality of life (16, 17). 
Preventing complications in patients with IIH often requires frequent contacts 
with healthcare providers (ophthalmologists, neurologists and sometimes neuro-
surgeons). Friesner et al (13) report that the IIH disorder causes a substantial cost 
both for society and the individual due to direct healthcare costs (check-ups, high 
need of hospital admissions and sometimes surgical procedures such as ventricu-
loperitoneal (VP) shunt and shunt revisions) and personal costs (loss of income) 
as well as indirect costs (change of work due to impaired health). A recent British 
study by Mollan et al also revealed substantial and increasing health care costs 
(a five-folded increase over 13 years) in this patient group (14). Indirect costs for 
the disorder have however not been addressed in European settings.
1.6 Treatment
Until recently, there was no consensus on how IIH should be optimally treated. 
Randomized trials are very scarce (101). Historically, there have been few trials 
available that compare different treatment regimes. To date there are however 
some trials ongoing and in the past years some consensus guidelines have been 
published (102-104). There is consensus on IIH that investigation and treatment 
of an eventual underlying cause is of major importance (obesity if present and 
eventual other causes or risk factors that might be present). Also, symptomatic 
treatment of the high intracranial pressure and its symptoms as well as securing/
preserving vision is the focus when dealing with this patient group, with rapid 
surgical intervention if vision is threatened.
1.6.1 Acetazolamide
The first line treatment for IIH is acetazolamide. It is often started as soon as a 
patient is diagnosed with the disorder and shows symptoms of affected vision. It 
is titrated to high doses in order to lower intracranial pressure. The first random-
ized trial on 165 IIH patients with mild visual loss, the (NORDIC) IIH study, 
investigated the effect of acetazolamide treatment plus diet versus placebo and 
diet (105). This study showed a significant though modest improvement in visual 
function and provides the first evidence that acetazolamide is effective in lower-
ing ICP in IIH patients. Acetazolamide works as a carbonic anhydrase inhibitor 
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and effects the choroid plexus reducing CSF production and thereby lowering ICP 
(94). Treatment with acetazolamide however renders frequent side effects which 
often affects patient compliance. Common side effects are paresthesias in hands 
and feet, loss of appetite (often resulting in weight loss), altered taste, nausea, 
metabolic acidosis, and fatigue. 
1.6.2 Topiramate
Topiramate is also recommended for treatments of IIH and has a similar mecha-
nism of action as acetazolamide. As a mild carbonic anhydrase inhibitor, it possibly 
reduces CSF production as well as improving IIH symptoms by weight loss (a com-
mon side effect of the treatment). There is one randomized small study (20 patients 
in each arm) comparing the effectiveness of topiramate and acetazolamide which 
showed no significant difference at 3, 6 and 12 months follow up (106). The most 
common side effects of topiramate are distal paresthesias, concentration difficulties/
cognitive impairment and weight loss. As topiramate also has the indication prophy-
lactic treatment for migraine, patients with both disorders might benefit from this 
treatment. Studies in rats have shown that topiramate lowered intracranial pressure 
more efficiently than other treatments such as acetazolamide and furosemide (107). 
1.6.3 Other oral medications in IIH
Sometime use of acetazolamide in combination with other diuretics have been 
tried, for example furosemide, however such treatments have not been evaluated 
in controlled studies. Short term treatment with corticosteroids in patients with 
severe visual disturbances has been reported and sometimes used but is nowadays 
uncommon due to side effects including weight gain, which might in the long term 
worsen the IIH presentation (94). 
1.6.4 Weight reduction
Weight loss is the most important aspect of IIH treatment in obese IIH patients. It 
is shown that weight loss is associated with improvement of IIH symptoms (78, 
79, 81, 108-110). All overweight IIH patients should be advised and supported 
to lose weight and preferably be referred to dieticians or specialist centers with a 
focus on weight reduction.
1.6.5 Surgical treatment
Today surgical procedures should be strongly considered if there is risk of visual 
damage due to high ICP. The most commonly and traditionally used surgical treat-
ments for IIH are CSF diversion procedures and optic nerve sheath fenestration 
(ONSF). Recently, stent procedures of the sinus transverses have raised hope of 
new treatment for IIH, as well as gastric bypass to induce weight loss. 
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1.6.5.1 Shunt procedures
Of the available CSF diversion procedures, ventriculo-peritoneal shunt (VPS) 
procedure or lumbo-peritoneal shunt (LPS) are the most common. VPS procedure 
is associated with less complications and revisions compared to LPS procedures 
(111, 112); while the effect on headache and visual symptoms seems to be equal. 
Shunt procedures are regarded as effective treatment for high intracranial pressure 
and are most effective for treatment of acute visual symptoms. The most effec-
tive treatment for intractable headache and visual symptoms was if shunting was 
performed within two years of diagnosis and/or with obvious papilledema (112). 
The complication rate is however high with over 40% requiring additional surgery. 
A major complication rate was seen in 8% (for example shunt infection, tonsillar 
herniation, subdural hematoma, CSF fistula) and minor complications in 33% (56). 
1.6.5.2 Optic nerve sheath fenestration
ONSF is used to reduce papilledema-related visual loss; it does not lower ICP and 
therefore thought to be less effective on the headache component of the disorder. 
It shows good effectiveness on visual symptoms. It is a less invasive procedure 
than the CSF diversion procedures and does not have a high complication rate. In 
a review by Satti et al (56) they analyzed reported ONSF procedures in over seven 
hundred patients. Improvement of papilledema occurred in 80%, improvement of 
headache in 44% and visual improvement occurred in 59%. Major complications 
(eye muscle paralyses, retrobulbar/orbital hemorrhage et al) were only seen in 
1.5% of cases reported. Minor complications were reported in 16% of patients. 
1.6.5.3 Stent procedure of the venous sinus
Treatment with venous sinus stenting is a new promising treatment for refractory 
IIH first described by Higgins in 2002 (113). The procedure has since been per-
formed and results reported in many studies. In a recent meta-analysis (114), some 
473 patients from 24 studies were evaluated. Symptoms were generally shown to 
improve; for example, headache (76%), papilledema (86%), visual acuity (70%) 
and tinnitus (85%) all showed substantial improvements in reporting of symptoms. 
Major complications were observed in less than 2% of patients (subdural hematoma).
1.6.5.4 Bariatric surgery
Bariatric surgery has been proposed as an effective treatment option to help patients 
lose weight to improve IIH symptoms (78, 81, 110). In a review by Handley et al 
(115) summarizing the effect of bariatric surgery in IIH patients they saw improve-
ment of IIH symptoms in 95% of patients with data available suggesting bariatric 
surgery is a promising treatment regime for patients with IIH. However, bariatric 
surgery is not straightforward, so patients must be willing to implement dietary 
changes and fulfill the criteria for bariatric surgery prior to this treatment.
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 1.7 Epidemiological studies – Methodological 
considerations
Epidemiological studies help us study the natural cause of a disease and identify trends 
of a disease occurring. With epidemiological methods we also determine incidence 
and prevalence of a disorder in a population. We also use epidemiological studies to 
identify possible etiologies behind a disorder and allows for the study of effect and 
safety of treatments or disease prevention. We often study whether there is a connection 
between an exposure and the outcome. There are different types of epidemiological 
studies: observational or experimental. This thesis is comprised of only observational 
studies. The types and uses of observational studies are discussed in this chapter.
1.7.1 Types of observational epidemiological studies
1.7.1.1	 Descriptive	studies
In a descriptive study one observes and describes a specific phenomenon, for  example 
describe a condition or disease. It could be case reports, case series, or incidence 
studies. It is often useful if not much is known about a phenomenon, to identify 
patterns, and help create hypotheses for further studies. 
1.7.1.2 Cross sectional studies/prevalence studies
Cross sectional studies take measurements at one point in time and can be used for 
a variety of research questions. For example, assessment of whether associations 
between risk factors and disease can be undertaken. Cross-sectional studies are, 
however, limited in that temporality cannot be assessed, and therefore cannot give 
information on cause and effect. 
1.7.1.3 Case-controls studies
Case-control studies can be described as retrospective observational studies in that 
those with and without the outcome are identified (cases and controls respectively), 
and previous exposure to certain risk factors are then examined. It is important that 
the cases and controls are as similar as possible except for their outcome/ disease. 
With case control studies it is possible to study several exposures. This type of study 
is most convenient when investigating rare disorders because all cases are identi-
fied from study start, which is not the case for cohort studies. Several controls can 
be chosen per case. 
1.7.1.4 Cohort studies
Cohort studies are also observational but can be both retrospective (the exposure and 
outcome have already happened) or prospective (cohorts are identified through their 
exposure to an outcome/disease). Persons are defined as exposed or non-exposed and 
are followed over time to determine whether the outcome occurs. In cohort studies 
it is important that included participants are similar except for the exposure status. 
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These types of studies are generally considered better for rare exposures but can 
be underpowered when considering rare outcomes. 
1.7.2 Systematic errors
Bias is what we call systematic errors and can occur in any phase of the research, 
both in the study design phase, during data collection and when interpreting and 
analyzing the results. Publication bias could also be a factor when analyzing 
research as negative study results might be less commonly published. It is impor-
tant to identify and avoid bias when performing studies. There are mainly three 
broad types of bias; information bias, selection bias and confounding. 
1.7.2.1 Information bias
Information bias is when the information we collect about or from the study par-
ticipants is incorrect. Example of information bias could be: measurement errors, 
recall bias and interviewer bias. Non-differential misclassification bias is bias 
at random and is believed to affect both investigated groups similarly; in most 
cases affect our results by moving the point estimate towards the null. Differential 
misclassification however is non-random affecting for example exposed and non-
exposed differently and can give both an over- or under estimation of the associa-
tion, thereby resulting in either hiding or creating an association that is not valid. 
1.7.2.2 Selection bias
Selection bias appears when the selection of study participants is done in a way 
that it is not randomized, or the sample is not representative of the populations 
intended to study. Example of selection bias is: volunteer bias, loss to follow up, 
selection bias by death, healthy worker effect. This type of bias is common in 
case-control studies and can appear for example by the way study participants 
are selected or if they during inclusion not randomly choose to be included or to 
remain during the whole study period. For example, if we study the effect of a 
vaccine but included study participants that are mostly young healthy adults we 
include selection bias as the population that will probably most benefit from the 
vaccination are an older population with multiple comorbidities.
1.7.2.3 Confounding
A confounder is a factor that interferes with the study. It needs to be associated to 
the exposure and a risk factor for the outcome studied and cannot be in the causal 
pathway. A confounder cannot be caused by the exposure. If the factor however is 
in the causal pathway, it is called a mediator. A common example of confounding 
is for example if we are studying the relationship between alcohol consumption 
and cardiovascular disorder. Smoking would then be the confounder needing to 
adjust for as smoking is correlated to alcohol consumption but not caused by this 
exposure and smoking is a risk factor for cardiovascular disorder (the outcome), 
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see figure 3. Confounders could be known prior to study start and we should then 
try to adjust for them. Also, some confounders could be known to the researcher 
but not possible to adjust for, and we might also have unknown confounders. 







To adjust for confounders, we can do this from study start by study design or at 
the end by different analyzing methods. From the start we can use technics such 
as randomization (in for example randomized trials) or adjust for confounders by 
means of how we choose our study participants. This we can do by using  restriction 
(only including for example women of certain age, or only non-smokers, a method 
that however affects the study’s generalizability) or by matching cases with con-
trols on certain factors. We can also at end of study investigate whether we have 
confounding by doing: 
• stratification analyses (by age, gender or by other possible confounders that 
we suspect)
• regression analyses (statistical analyses adding other variables that we think 
might affect the factor we are investigating)
• sensitivity analyses (sub-group analyses)
• standardization (making exposure categories comparable by for example 
weighting the groups to the suspected confounder factor. Weighting is done 
against a standardized rate of how common that factor in the specific population 
we investigate).
1.7.3 Random errors
When we measure research data we get a point estimate. However, we do know 
that a point estimate is affected by variability in exposure and might be due to 
chance. To estimate random errors, we use statistical methods and often describe 
this variation by p-values or confidence interval to interpret the statistical varia-
tion. In our studies we use 95% confidence intervals.
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2 AIMS
The overarching aim of this thesis was to investigate risk factors associated with 
IIH to improve the knowledge base on which individuals may be at risk of dis-
ease development. A secondary aim was to evaluate IIH (incidence and clinical 
characteristics) in a Swedish context.
The specific aims of each study:
I. Validation of the IIH diagnosis (G93.2) in the Swedish National Patient 
Registry (NPR) as well as investigate the incidence and clinical characteristics 
of IIH in a Swedish County sub-population. 
II. Developing algorithms that with higher probability finds correctly diagnosed 
IIH patient in NPR, making registry studies more reliable. 
III. Investigating if conditions causing inflammatory activation are more frequent 
among IIH patients compared to matched controls the year prior to the diag-
nosis of idiopathic intracranial hypertension (IIH).
IV. Investigating the incidence of IIH in Sweden over time as well as studying if 
IIH patients are more frequently exposed to previously reported risk factors 




3.1 Setting and study populations
3.1.1.1 Study I and II 
All patients (≥18 years) with a diagnosis code of G93.2 registered for benign 
intracranial hypertension that had contact with specialized healthcare departments 
within the Stockholm County between Jan 1, 2006 to Dec 31, 2013 were included. 
Medical records were collected and reviewed with information gathered on year 
of diagnosis, presence of comorbidities and medication use the year prior to first 
diagnosis, presenting symptoms, age, sex, and investigation results. The diagnosis 
was validated according to the modified Dandy Criteria (3, 4). 
3.1.1.2 Study III and IV
All patients (≥18 years) with a diagnosis code of G93.2 registered for benign intrac-
ranial hypertension that had contact within specialized healthcare departments in 
Sweden during the years 2000 to 2016 and for whom the algorithms developed in 
study II predicted a correct diagnosis were included as IIH cases. For every case 
we selected five matched general population (GP) controls and five obese controls 
(that also had a diagnosis code for obesity (ICD-10-SE E66) in NPR). Matching 
factors were age, sex, region and vital status on the index date. Index date was 
defined as the date of IIH diagnosis for the case and same date used within the 
matched group. Cases were excluded if they had received a diagnosis of IIH prior 
to the year 2000. Controls were also excluded if they received a diagnosis code 
of IIH prior to index date.
3.2 Data sources
3.2.1 Swedish registers
Registers have a long tradition in Sweden. As early as the seventeenth century, 
people in Sweden were registered in church books to keep a record of parish 
members, and in the eighteenth century this was further formalized into an official 
authority to produce population statistics, the first of its kind in the world (116). 
In Sweden every citizen is assigned a unique ten-digit personal identity number 
(PIN) (Swedish: personnummer) since the year 1947 (117). The PIN enables  linkage 
between many national registers and forms a unique base for medical research. 
3.2.1.1 The total population register (TPR)
The Total Population Register (TPR, in Swedish: Folkbokföringsregistret) started 
collecting data from 1968. It contains data on PIN, name, place of birth (country, 
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county and parish), citizenship, place of residence, sex, age, registration of migra-
tion (date, country, ground for settlement), death, and relations (marital status, 
child-parent information, guardian, adoption) (40). This register is part of Statistics 
Sweden (SS, in Swedish: Statistiska centralbyrån).
3.2.1.2 The Swedish National Patient Register (NPR)
In 1964 the NPR (Swedish: Patientregistret) was founded. It has national cover-
age from 1987 regarding inpatient care and from the year 2000 it also includes 
outpatient data. Today it registers all specialized inpatient and outpatient contacts, 
but not primary care contacts. Studies of the inpatient register validity is gener-
ally good with a PPV of 85-95 % for most diagnoses, although accuracy is vari-
able depending on the diagnosis (118). In the inpatient register a missing primary 
diagnosis is ≤1% (118, 119). The proportion missing is higher in the outpatient 
register. Initially, in 2001, 25-30% of main diagnosis were missing, however in 
recent years only about 3% are missing (119).
The register contains data on PIN, age, sex, date of admission and date of discharge, 
hospital, clinic, main and secondary diagnoses, and procedure codes (119). ICD-
10-SE coding has been used since 1997 (118). The register is held by the National 
Board of Health and Welfare (NBHW) in Sweden (Swedish: Socialstyrelsen). 
3.2.1.3	 The	Swedish	Prescribed	Drug	Register	(PDR)
The PDR (Swedish: Läkemedelsregistret) started July 2005 and contains informa-
tion on pharmacological prescriptions sent to pharmacies in Sweden including 
prescribed care-related consumables. The register contains data on PIN, sex, age, 
place of residence, item (name of pharmacological drug, ATC-code, dose, number 
of items prescribed), prescription information (amount of prescribed drug, date 
of prescription, date of collected drug from pharmacy), costs, and information 
on type of clinical setting, including the profession of the prescriber (120). This 
register is also held by the NBHW in Sweden.
3.2.1.4 The Swedish Medical Birth Register (MBR)
The MBR (in Swedish: Medicinska födelseregistret) started in 1973. 97-99% of all 
births in Sweden are reported in the register. It provides data on the mother (among 
other data PIN, age, smoking habits, cohabitation status, previous pregnancies), 
pregnancy length (full weeks + number of days over full weeks), date of delivery 




3.3.1 Diagnostic criteria for IIH
We chose to use the modified Dandy Criteria (3, 4) in our studies (see table 1 in 
background section 1.1). The new proposed criteria by Friedman (5) were not 
adopted in our studies for four main reasons: 
1. the criteria are still under debate
2. other reference studies have used the old criteria
3. the new criteria include radiological descriptive terms not regularly described 
in older radiology reports, which would result in lots of missing data
4. the main purpose of our study was to investigate whether associated comorbidities 
and medications truly is associated with IIH.
The modified Dandy Criteria were used when validating the diagnosis code in 
Study I by reviewing medical records. 
3.3.2 Study design study I
Study I was a validation and descriptive study on patients with an IIH diagnosis 
in Stockholm County 2006-2013. All patients with a diagnosis code of G93.2 in 
the NPR were included and the diagnosis was validated by medical record review. 
As a quality control, 10% of the records were randomly selected and reviewed by 
a second neurologist blinded to the valuation. 
3.3.3 Study design study II
Patients from study I (≥18 year of age for whom the diagnosis code had been 
validated, n=207)) were included and randomized into two groups; one used to 
produce the algorithm (n=105) and one for validation (n=102). We tested vari-
ables that was possible to extract from registries that we thought could be useful 
to better predict which patients should be included in registry studies.
3.3.4 Study design study III + IV
These studies used a case-control study design, including all IIH patients diagnosed 
2000-2016 as cases. Exposures were risk factors for IIH development. Exposure 
were identified using register codes the year prior to index date (first diagnosis 
of IIH). ICD-10-SE diagnosis codes were used to identify diagnoses in the NPR, 
and ATC-codes on drug composition were used to identify prescriptions within 
the PDR. Study IV also investigated incidence of IIH over time. Risk factors that 
we investigated were disorders causing inflammatory activation (study III) as well 
as previously reported risk factors for IIH (study IV). 
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3.3.4.1 Choosing of risk factors for study III
The reason for choosing inflammation was related to the results of study I (in this 
study we found many exposures related to disorders causing inflammation) and 
inflammation had been a hypothesized factor in the literature. From study I alone, 
we did not know if exposure to disorders causing inflammation in IIH patients differs 
relative to what would be an expected exposure rate. We therefore speculated that 
inflammation could act as a risk factor and decided to investigate this. (See included 
diagnoses by ICD-10-SE coding and treatments by ATC coding in appendix 9.1). 
3.3.4.2 Choosing of risk factors study IV
Previously reported risk factors were chosen based on review articles, results from 
previous case-control studies, case reports of risk factors and proposed secondary 
causes (5, 58-62, 122). One risk factor that we would have liked to investigate, 
apart from those included, was obstructive sleep apnea syndrome (OSAS) since this 
diagnosis was seen in 21% of male patients in study I. Unfortunately, this diagnosis 
code was missed on the acquisition of diagnosis codes from NPR and therefore not 
available to us. (See included risk factors by ICD-10-SE coding and ATC coding 
in Appendix 9.2). 
3.4 Statistical analyses
3.4.1 Incidence and age differences (study I and IV)
Incidence was calculated by dividing new onset cases per year with the total 
Stockholm County population ≥18 years old (study I) or the total populations ≥18 
years old (study IV) in Sweden at the end of December that year (official statistics 
available from Statistics Sweden) and multiplied by 100,000. In study I we calculated 
the confidence interval for the mean incidence using the variance for the time-period 
2006-2013. Age differences by sex were calculated using a univariate linear regres-
sion model using age as a continuous outcome and sex as the independent variable.
3.4.2 Development of algorithms (study II)
The binary variable for a correct or incorrect diagnosis was used as the outcome 
in a forward stepwise logistic regression model (figure 4). The variables available 
in the national registers (NPR and PDR) which we believed to be useful predictors 
of a correct IIH diagnosis were included as covariates. This approach meant that 
variables which did not significantly improve the fit of the model were removed. 
We tested the following covariates to produce algorithm 1 (variables that could be 
drawn from both the NPR and the PDR): age, sex, number of diagnosis codes being 
recorded (at least two, three or five times), and if patients had received Acetazolamide 
treatment. Algorithm 2 contained the same variables except for Acetazolamide 
treatment making us independent of the PDR for this algorithm. We constructed 
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numerous models and selected the one which most frequently correctly predicted 
whether the patient had true IIH or not. We obtained predicted probabilities using 
the outcome of the model for the algorithm group and applied predicted probabili-
ties to the test group based on patient characteristics for the variables included in 
the algorithm. The different algorithms produced were evaluated by calculating 
how well they were predicting both true and incorrect IIH combined (predictive 
probability value). Positive predictive value (PPV) and negative predictive value 
(NPV) with 95% confidence intervals (CI) were also evaluated.
Figure 4. Forward stepwise logistic regression model.
3.4.3 Case-controls studies on risk factors (study III and IV)
If at least one of the two algorithms predicted correct diagnosis of IIH they were 
included as IIH cases in the register studies. Patients were excluded if they had a 
previous IIH diagnosis recorded (1997-1999). Conditional logistic regression was 
used to estimate odds ratios (OR) and 95% confidence intervals (CI) comparing 
IIH to GP controls as well as comparing IIH to obese controls. This model assumes 
clustering within the matched groups and the variance is adjusted accordingly. 
The frequency was reported. As a proxy for socioeconomic status the adjusted 
model included educational level (categorized as level 1: ≤ 9 years of compulsory 
school, level 2: > 9 year of compulsory school and ≤ high school, level 3: > higher 
education after high school). 
3.5 Ethical approval
All studies were approved by the ethical committee in Stockholm. In study I addi-
tional local approval was given by each head of the different clinical departments 
before receiving permission to review medical records. 
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4 RESULTS
4.1 Validation of IIH diagnosis
Study I focused on validation of the IIH diagnosis coding in the NPR, using the 
modified Dandy Criteria. See inclusion chart, figure 5. 
We found a low PPV of 65.2% (95% CI: 58.4-71.4) of a correct IIH diagnosis when 
validating the registered codes for IIH in the NPR by medical record review. As 
many as 14% had a wrong code (given by mistake), 13% were initially suspected 
as being IIH but later received a different diagnosis code, and 8% received the 
code for IIH but had an obvious cause explaining the high intracranial pressure, so 
called secondary intracranial hypertension (sIH). 0.5% had an unclear diagnosis 
which was not possible to validate from records. 
Figure 5. Inclusion chart study I.
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4.2 Incidence and onset of IIH
4.2.1 Increasing incidence
In study I the average yearly incidence in Stockholm county was 0.65 (CI 0.57- 
0.73) per 100,000 adult inhabitants. Results were similar for the whole of Sweden 
when looking at the national register data in study IV with an average yearly 
incidence of 0.71 per 100,000 adult inhabitants. When looking at the incidence 
over time in study IV we saw an increasing incidence overall, especially evident 
among females age 18-45, shown in figure 6 and table 5.


















populaon over ≥ 18 year women 18-45 year
Year
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Table 5. Incidence by time-period in the adult population, and for females 18-45
Population: Mean incidence / time-period: Mean incidens:
2000–2005 2006–2011 2012–2016 2000–2016
Population over ≥18 0.53 0.70 0.95 0.71
Women aged ≥ 18 to ≤ 45 1.66 2.23 3.32 2.35
4.2.2 Obesity
In study I obesity was common. Unfortunately, a precise value of BMI was missing 
in many medical records (in 30% of definitive and 83% of probable IIH). Mean 
BMI in those with precise values were 34.4 kg/m2 (definite IIH), and 38.1 kg/m2 
(probable IIH). However, when including subjective definitions such as obese or 
overweight we found that 92% of patients with an IIH diagnosis were overweight 
or obese (data available for 103 out of 135 patients). 
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4.2.3 Age at diagnosis and sex difference
In study I when evaluating IIH in Stockholm County a female to male ratio of 
6.1:1 was observed. Women were also on average younger than men at the time 
of diagnosis; the mean age at diagnosis for females was 31.0 (CI 28.8-33.1), and 
for males 42.9 (CI 36.4-49.5), p<0.001. Similar results were seen in the large 
national register study with a female to male ratio of 6.6:1 and mean age at time 
of diagnosis for women of 31.5 (CI 31.3-31.7) with males slightly older at 36.2 
(CI 35.5-36.9). 
4.2.4 Educational level
Educational level differed significantly among IIH patients compared to GP con-
trols. The educational level of IIH patients was more similar to the obese controls, 
see table 6. We analyzed education as a proxy for socioeconomic status and used 
this data in the adjusted model for the odds ratios (OR). 
Table 6. Information on achieved highest educational level
Information on achieved highest 







Compulsory school (≤ 9 years) 163 (18.4%) 439 (9.9%) 766 (17.2%)
Upper secondary (high school) 447 (50.4%) 1853 (41.6%) 2408 (54.1%)
University (level above high school) 277 (31.2%) 2162 (48.5%) 1279 (28.7%)
4.3 Algorithm
We tested different covariates possible to extract from registers that we believed 
could be helpful in better predicting which patients had a correct IIH diagnosis. 
The forward stepwise logistic regression model kept the following covariates that 
significantly improved model fit: age, number of times the diagnosis code G93.2 
was recorded, and acetazolamide treatment. We chose to produce two algorithms 
(one without and one including drug register data). See table 7 below for informa-
tion on how well the algorithms predicted whether a patient was true IIH according 
to number of recorded diagnosis codes. We chose to use three or more G93.2 as 
the covariate in our defined algorithms.
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Table 7. Algorithms tested according to times of recorded diagnosis code
Prediction of correct diagnosis
Patient and prescription registry* 
(Algorithm 1):
Algorithm given 
 correct prediction 
% (95% CI)
PPV% (95% CI) NPV% (95% CI)
A 2 or more codes 88.2 (80.3-93.2) 89.7 (79.8-95.0) 85.3 (69.0-93.8)
B 3 or more codes 88.2 (80.3-93.2) 89.7 (79.8-95.0) 85.3 (69.0-93.8)
C 5 or more codes 80.4 (71.5-87.0) 82.4 (71.3-89.7) 76.5 (59.4-87.8)
Prediction of correct diagnosis
Patient registry only** 
(Algorithm 2):
Algorithm given 
 correct prediction 
% (95% CI)
PPV% (95% CI) NPV% (95% CI)
D 2 or more codes 85.3 (77.0-91.0) 91.2 (81.6-96.0) 73.5 (56.3-85.7)
E 3 or more codes 86.3 (78.1-91.7) 91.2 (81.6-96.0) 76.5 (59.4-87.8)
F 5 or more codes 82.4 (73.6-88.6) 83.8 (73.0-90.9) 79.4 (62.5-89.9)
PPV = positive predictive value, NPV = negative predictive value, CI = 95% confidence  interval. 
* Models contain variables: age, ever exposed to Acetazolamide treatment and specified  number 
of times receiving ICD-10 code G93.2. ** Models contain age, specified number of times receiving 
ICD-10 code G93.2.
The algorithms predicted our definite IIH patients very well and was good at 
identifying those with a wrong diagnosis code or just an initial suspicion that later 
changed to another diagnosis (see table 8). However, the algorithms only predicted 
correctly in 60% of the sIH patients and had difficulty predicting probable IIH. 
Table 8. Correct prediction IIH diagnosis (yes or no) according to validated diagnosis 
results
Validated diagnosis results: Algorithm 1 correctly 
 predicted IIH status
% (95% CI)
Algorithm 2 correctly 
 predicted IIH status
% (95% CI)
Definite IIH 94.7 (84.4-98.4) 93.0 (82.3-97.4)
Probable IIH 63.6 (28.8-88.3) 81.8 (42.0-96.6)
sIH 60.0 (8.1-96.2) 60.0 (8.1-96.2)
Wrong diagnosis code* or initial suspicion** 90.9 (46.3-99.2) 81.8 (42.0-96.6)
Algorithm 1 comprise of variables: age + receiving diagnosis code G93.2 three or more times 
and exposure to Acetazolamide treatment. Algorithm 2 comprise of variables: age +  receiving 
diagnosis code G93.2 three or more times. CI = 95% confidence interval. Definite IIH,  idiopathic 
intracranial hypertension fulfilling modified Dandy Criteria; Probable IIH, overall  clinical descrip-
tion in great concordance with IIH but with some missing data in medical records; sIH, second-
ary intracranial hypertension. *Patients seeking medical attention for another diagnosis but 
received code G93.2 (IIH). **Initial suspicion of IIH that later changed to other diagnosis or 
not sufficient workup.
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4.4 Risk factors in association to IIH
4.4.1 Descriptive study I
In study I we found obesity and female sex to be the most common risk factors (see 
above). According to frequency we also found that having recently been exposed 
to an infection was common (present in 21%). Both obesity and infections cause 
inflammatory activation. Other disorders associated with inflammation, such as 
asthma, allergy, systemic lupus erythematosus (SLE), pancreatitis, inflammatory 
bowel disorders, and psoriasis were also common as comorbid disorders at IIH 
presentation. In men with IIH comorbidities such as hypertension (42%), diabetes 
(26%), and OSAS was common (21%).
4.4.2 Case-control studies III and IV
In the case-control studies (study III and study IV) we included after use of algo-
rithms: 902 IIH cases and 4510 matched GP controls and 4510 obese controls. In 
the analyzes performed to study drug dispensing’s, 654 IIH cases were included and 
a corresponding 3270 GP and obese controls, respectively. Study III  investigated 
infectious and inflammatory disorders as possible risk factors for IIH development 
while study IV investigated factors previously proposed in the literature as risk 
factors for IIH development (disorders, drugs and pregnancy). Included ICD-10-SE 
diagnosis codes and ATC codes are shown in appendix section 9.1-9.2. 
4.4.3 Infectious and inflammatory disorders 
Both exposure to inflammatory and infectious disorders were significantly more 
common in IIH patients compared to both control groups the year prior to the 
first diagnosis of IIH. When comparing IIH patients to GP controls, the odds for 
exposure to infections were: ORadjusted=4.3 (95% CI 3.3-5.6) and for inflamma-
tory conditions ORadjusted=3.2 (95% CI 2.4-4.3). Compared to obese controls IIH 
patients also had increased odds, however the magnitude of the effect was reduced: 
infectious disorders ORadjusted=2.6 (95% CI 2.1-3.3) and inflammatory disorders 
ORadjusted=2.4 (95% CI 1.8-3.2). When doing sensitivity analyses on exposure to 
any infectious or inflammatory disorders and how many times they received any 
of these codes in the preceding year we found that the OR for developing IIH 
increased with having received three or more codes compared to only one code 
(see figure 7). Sensitivity analyses looking at drug dispensing for drugs used to 
treat inflammatory and infectious disorders supported our findings with increased 
OR for exposure to these drugs in IIH patients compared to controls, see figure 8. 
We also performed a sensitivity analyzes by looking at exposure to antibiotics 
when excluding antibiotics reported to be risk factors for IIH (i.e. excluding 
 tetracyclines, sulfonamides and fluoroquinolone antibiotics) but our results did 
not change materially in this analysis.
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Figure 7. Frequency of receiving a code for any infectious or inflammatory disorder 
in the preceding year before index IIH code.
Adjusted OR with 95% CI in parenthesis. Adjustments made for educational level. 
Figure 8. Odds ratio of dispensations from pharmacies one year prior to  diagnosis 
(index date) in IIH patients compared to GP controls and compared to obese controls.
IIH vs GP controls antibiotic and antiviral treatments
IIH vs obese controls antibiotic and antiviral treatments
IIH vs GP controls antibiotic treatments
IIH vs obese controls antibiotic treatments
IIH vs GP controls systemic corticosteroids
IIH vs obese controls systemic corticosteroids
IIH vs GP controls NSAIDs
IIH vs obese controls NSAIDs
IIH vs GP controls GI inflammatory drugs















Adjusted OR with 95% CI. Adjustments made for educational level.
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4.4.4 Proposed risk factor disorders and pregnancy exposure 
Looking at previously reported risk factors we found a significantly increased risk 
of exposure to most of these disorders. The ORs were greater when comparing 
with GP controls relative to obese controls in all disorders except for kidney failure 
where results were similar for IIH patients compared to both control groups. In 
ovary dysfunction including PCOS the OR compared to obese controls did not reach 
significance as compared to GP controls. There was no difference in pregnancy 
exposure when comparing IIH patients with both control groups (see figure 9). 
Benign skin tumors were analyzed as a sensitivity analysis being a disorder that 
we did not expect to have any association to either IIH, inflammation nor obesity. 
Benign skin disorders were slightly more common in IIH patients but did not reach 
significance compared to obese controls and borderline significance compared to 
GP controls, see figure 9. 
Figure 9. Forest plots visualizing adjusted ORs in IIH cases compared to GP and 
obese controls.
Arterial hypertension:     IIH vs GP controls
Arterial hypertension:     IIH vs obese controls
Coagulopathy:     IIH vs GP controls
Coagulopathy:     IIH vs obese controls
Iron anemia:     IIH vs GP controls
Iron anemia:     IIH vs obese controls
Kidney failure:     IIH vs GP controls
Kidney failure:     IIH vs obese controls
Ovary dysfunction incl PCOS:     IIH vs GP controls
Ovary dysfunction incl PCOS:     IIH vs obese controls
Pregnancy exposure:     IIH vs GP controls
Pregnancy exposure:     IIH vs obese controls
Systemic lupus erythematosus:     IIH vs GP controls
Systemic lupus erythematosus:     IIH vs obese controls
Benign skin tumors:     IIH vs GP controls

















Odds ratio (95% CI)
  1.1 10
Exposure to proposed risk factor disorders/pregnancy
Adjusted OR with 95% CI. Adjustments made for educational level. Results also for 
 sensitivity analysis done on benign skin tumors. 
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4.4.5 Proposed risk factors in drug treatments 
When looking at the exposure to previously reported possible risk factor drugs 
we found significantly increased ORs for exposure to lithium, corticosteroids, 
antibiotics (tetracyclines, sulpha drugs, quinolones). Exposure to androgen treat-
ments was rare with large confidence intervals but significantly increased com-
pared to GP controls and border significant compared to obese controls. Exposure 
to contraceptives were in fact lower than in the control groups. As a sensitivity 
analysis we also analyzed exposure to drugs used to treat arterial hypertension and 
iron anemia deficiency due to that these disorders often are being diagnosed and 
treated in primary care settings. Increased odds in arterial hypertension treatments 
confirmed our results on arterial hypertension diagnosis, however results for iron 
anemia treatments were divergent with higher odds compared to GP controls but 
lower odds compared to obese controls. Results are shown in figure 10. 
Figure 10. Forest plots visualizing adjusted ORs in IIH cases compared to GP and 
obese controls on exposure to risk factor drugs.
Androgen treatments:     IIH vs GP controls
Androgen treatments:     IIH vs obese controls
Contraceptives:     IIH vs GP controls
Contraceptives:     IIH vs obese controls
Lithium:     IIH vs GP controls
Lithium:     IIH vs obese controls
Sulfonamides:     IIH vs GP controls
Sulfonamides:     IIH vs obese controls
Systemic corticosteroids:     IIH vs GP controls
Systemic corticosteroids:     IIH vs obese controls
Tetracyclines:     IIH vs GP controls
Tetracyclines:     IIH vs obese controls
Quinolones:     IIH vs GP controls
Quinolones:     IIH vs obese controls
Antihypertensive treatments:     IIH vs GP controls
Antihypertensive treatments:     IIH vs obese controls
Iron anemia treatments:     IIH vs GP controls



















Odds ratio (95% CI)
  1.1 10
Exposure to proposed risk factor drugs
Adjusted OR with 95% CI. Adjustments made for educational level. Results also for sensi-
tivity analysis on antihypertensive and iron anemia treatments. 
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5 DISCUSSION
Epidemiological studies are important in gaining understanding into rare disorders 
such as IIH. They are used to improve our knowledge on for example incidence, 
describe characteristics of a disorder, and provide hypotheses on factors that influ-
ence the disorder. It can also be used to evaluate outcome and changes over time. 
5.1 Descriptive part – the patient cohort and validation
5.1.1 IIH cohort – variation in disease course and healthcare
Study I, the retrospective descriptive study, by evaluating medical records of large 
numbers of IIH patients with this rare disorder gave an important understanding 
of the complexity of the IIH disorder. 
There were large variations in both how long patients had ongoing symptoms 
before receiving the diagnosis, and regarding the disease course between individual 
patients. It was also obvious that investigations, treatments, and follow-up routines 
differed. These decisions varied between doctors in charge and there were large 
variations in medical actions taken, even when it appeared that cases were quite 
similar. This could be due to both a lack of evidence-based guidelines for IIH, and 
that it is a rare diagnosis with few cases to gain experience from for the individual 
physician. Furthermore, the combination of the varied disease presentations, and 
the fact that several disciplines are involved in the patient’s care (neurologists, 
ophthalmologists, neurosurgeons) is a challenge for equal care. 
Because of this we saw a need for better guidelines for the IIH disorder in Sweden. 
We organized a multidisciplinary meeting at Karolinska University hospital with 
specialists in neurology, neurosurgery, neuroradiology, neuroophthalmology, and 
neuropediatrics attending. Subsequently, this resulted in the development of the 
first Swedish national guidelines for IIH (103). Simultaneously other countries 
were doing similar work resulting in new published guidelines in recent years 
(102, 104). Guidelines are important to improve clinical management and equal 
care for this patient group as well as help to evaluate current care regimes and 
facilitate improvements for this group of patients in the future.
5.1.2 Age and sex difference 
We found an interesting age difference with males being older compared to females 
at time of diagnosis. This was most evident in study I but remained significant 
in study III. Some studies have also reported a similar significant age difference 
when comparing females to males (14, 123), others with a tendency to similar 
results (11, 26) and a few without this finding (124, 125). 
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In study I males had much higher frequency of cardiovascular disorders such as 
hypertension (42% in men and 8% in women) and diabetes (26% in men and 3% 
of women) as well as OSAS (21% in men compared to 0 cases among females). 
Regarding the seen differences among females and men in study I we speculate 
that risk factors of importance for IIH development might vary between the sexes 
and would be of interest for further studies. 
OSAS has previously been associated with IIH in men (11, 61) and has been 
speculated to have pathophysiological implications in the IIH disorder (126). 
One small study however did not find that the prevalence of OSAS in IIH patient 
was higher than controls (127). Looking into OSAS and comparing to matched 
controls would have been of high interest in study IV but unfortunately, we did 
not have that data available. 
Arterial hypertension is described to be common in IIH patients over age of 40 
(128) and this could partly explain the differences seen in study I. We did analyze 
a possible sex difference on arterial hypertension on our data in study IV. In both 
females and men respectively, arterial hypertension was found to be much more 
common in IIH patients compared to matched controls. The results for females 
compared to GP controls for arterial hypertension was OR=16.1 (95% CI 9.0-29.0) 
and for men (OR=27.4 (95% CI 9.4-79.3). Compared to obese controls OR for 
arterial hypertension was for women (OR=5.4 (3.5-8.2)) and for men (OR=4.6 
(2.4-8.7)). As confidence intervals are overlapping we could not conclude that sex 
influence this risk factor.
5.1.3 Educational level
Educational level differed among IIH patients compared to GP controls. As it was 
more similar compared to obese controls we believe that this appears to indicate 
some type of relationship between obesity and educational level. To our knowledge 
educational level in comparison with controls has not been investigated before 
in IIH patients, however living in socially deprived areas has been studied. Both 
 living in socially deprived areas and educational level are often used in studies as a 
proxy for socioeconomic status. In the study by Mollan et al (14) it has been shown 
that IIH patients to a much larger extent were living in what has been described 
as socially deprived areas; as many as 53% of diagnosed patients were living in 
the quantile 1 or 2 = the most social deprived areas in a scale of five quintiles. We 
believe this likely reflects that persons living in socially deprived areas have a 
higher prevalence of obesity and therefore have higher incidence of IIH. Living in 
a socially deprived surrounding is likely to provide less resources to achieve higher 
education. However, we cannot rule out that longstanding symptoms (headache, 
cognitive function) before receiving a diagnosis in some individuals might have 
affected ability to perform in school. 
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5.1.4 Female sex and obesity
Female sex and obesity are the main two risk factors associated with IIH. This 
was also confirmed in our studies. Regarding female sex, 85% (study I) and 86% 
(study III/IV), of IIH patients were females. Similar results with female predomi-
nance with a variation between 76-98% have been reported in other descriptive 
studies (8, 14, 22-26). We could only study obesity in study I and unfortunately a 
precise value of BMI was missing in many medical records. However, if including 
subjective definitions such as obese or overweight we found that 92% of patients 
with an IIH diagnosis were overweight or obese (data on 103 out of 135 patients). 
Other studies confirm the strong association with obesity/overweight among those 
with information on weight (71-100%) (22, 23, 26).
5.1.5 Validation
Study I was primarily a validation study of the registered IIH diagnosis in the 
NPR. We found that only 65% had a correct code according to the modified Dandy 
Criteria. Problems with validity of registered diagnosis codes and change of diag-
nosis codes during investigation and follow-up of patients have been demonstrated 
before as mentioned in the background section (1.2.3) (29, 30). Therefore, there 
was a need for a method to enable better choosing which patients to include in our 
registry studies. This challenged us to produce the algorithms that we then applied 
in studies III and IV to improve probability of which patients to include as correct 
IIH cases. The algorithms improved prediction to 86-88%. 
The algorithms performed best in correctly selecting patients with definite IIH 
(93-95%) and discarding cases with just a wrong diagnosis code or with an initial 
suspicion that later received another diagnosis (82-91%). In study I both incident 
and prevalent/previously diagnosed cases were included. The results showed 
that the algorithms worked less well in probable IIH maybe because 74% of the 
 probable cases in study I were prevalent cases with the majority (57%) of those 
cases having less than 3 codes registered and therefore less contacts with health-
care, (showing only 64-82% correct prediction). As we only included incident 
cases in study III and IV we believe the algorithms might have worked better at 
selecting IIH patients. 
The algorithms were the least successful in predicting sIH (60%). We believe 
this is due to these patients often having similar symptoms and treatments as IIH 
patients and often a more precise diagnosis code for their repeated visits is lack-
ing in ICD-10-SE. 
Altogether, validation of registered diagnoses and algorithms were found to be 
useful when performing register studies on a diagnosis such as IIH that initially 
may be difficult to diagnose correctly. In IIH, given that both the outcome of the 
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eye examination and ICP examination can be heterogenous depending on experi-
ence and sometimes uncertain results, and that several causes resulting in a sIH 
diagnosis might not be obvious on first visit, this is especially important to con-
sider. The IIH disorder almost certainly causes multiple contacts with healthcare. 
Therefore, we believe the most evident parameter that should be used in register 
studies in this patient group is having received the diagnosis code on several occa-
sions to be included as an IIH patient. 
5.2 Incidence of IIH
Our results showed an increase in IIH incidence over the years from 2000 to 2016 
with an 80-100% increase in overall incidence among all adults 18-45 years old. 
A similar increase has been reported in many recent studies (14, 24-26). However, 
Sweden seems to have a somewhat lower incidence with a mean incidence of 
0.71 per 100,000 inhabitants. This lower incidence seems to be related to lower 
reported prevalence of obesity in Sweden compared to the other nations that also 
have reported higher IIH incidence. A meta-analysis found an almost linear cor-
relation between incidence of IIH and obesity prevalence when analyzing data 
from several regions (129). 
As in other studies the highest incidence in the Swedish cohort was found among 
young females of reproductive age, 2.35 per 100,000. Unfortunately, we do 
not have data on BMI/overweight in Swedish registers, but other studies have 
shown that the incidence increases substantially if only looking at obese females 
of  reproductive age, with incidence between 22-38 per 100,000 (24-26). Since 
our study used algorithms to analyze the incidence we cannot exclude that some 
cases with IIH might not have been included and our results could therefore be an 
underestimation. However, considering results of previous validation studies of 
correctness of IIH diagnosis (see discussion above) this might well apply to other 
incidence reports with a possible reverse problem (overestimation). 
5.3 Risk factors for IIH
Better understanding of factors that might trigger IIH is of great importance in a 
disorder with an apparent multifactorial pathogenesis such as IIH where the patho-
physiological processes remain unknown. To summarize and discuss our results 
according to common denominators and in relation to possible hypotheses in the 
literature, see the modified directed acyclic graph (DAG) (figure 11). 
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Possible pathways in developing IIH:
1) The confirmed risk factors found to be associated with IIH in themselves are 
in the causal pathway (not knowing the physiological explanation)




c. intracranial pressure regulations 
3) Both 1) and 2) (multifactorial pathogenesis)
To visualize the uncertainties the DAG has orange arrows for previously proposed 
pathways and blue for newly proposed underlying pathways. 










Venous stenosis sinus transversus
SLE
Kidney failure/uremia
Proposed risk factors for IIH
Pathophysiological hypothesis
Proposed risk factor pathways
Bipolar disorder
Lithium
Abbreviations: SLE = systemic lupus erythematosus, PCOS = polycystic ovarian syndrome
5.3.1 Inflammation hypotheses
In study I we described which comorbidities were found in the IIH population at 
the time of diagnosis. A common denominator was disorders causing inflamma-
tory activation, such as infectious disorders, and other disorders such as asthma, 
pancreatitis, appendicitis, inflammatory bowel disease and so forth. Also, obesity 
(being the most common risk factor with the strongest association to IIH) is a dis-
order known to cause inflammatory activation (84) which provided the impetus 
for us to investigate this hypothesis. In study III we investigated how common 
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conditions causing inflammatory activation were in IIH cases compared to con-
trols and found that overall there was a significantly increased OR for having any 
infectious or inflammatory condition recorded. Even higher increased ORs were 
seen for having ≥3 number of codes of any infectious or inflammatory diagnosis 
registered compared to only one code the year prior to index date. One specula-
tion explaining this could be that having several codes could possibly implicate a 
more severe inflammatory activation needing repeated contacts with health care or 
having multiple disorders with inflammatory activation that could increase the risk 
of IIH development. Increased ORs were seen with both infectious and inflamma-
tory conditions compared to both GP and obese controls. However, among obese 
controls the effect size was lower. We also evaluated inflammatory conditions 
from different organ systems and found increased OR in all except for infectious 
and inflammatory conditions of the female reproductive organs that did not turn 
out to be significant compared to either of the two control groups. We therefore 
do not think that it is of relevance where the infection/inflammation is localized. 
In study IV which considered various previously reported risk factors, we found 
not only significantly increased ORs among disorders causing inflammatory activa-
tion but also of treatments used to treat infections/inflammatory disorders. Among 
those disorders systemic lupus erythematosus (SLE) is a systemic inflammatory 
disorder. It is also reported that inflammatory activation is seen in the adipose 
tissue regardless of obesity level in kidney failure/uremia (130). Additionally, in 
several pharmacological treatments the conditions for why the drug is dispensed 
is associated with disorders causing inflammatory activation and this could be 
the pathophysiological explanation behind the association. For example, the anti-
biotics associated with IIH (tetracyclines, sulphonamides and quinolones) are used 
to treat infections causing inflammatory activation, and corticosteroid treatment 
are used for treating conditions causing inflammatory activation. Even the risk 
factor lithium treatment could potentially have an increased risk associated with 
inflammatory activation since bipolar disorders, for which lithium primarily is 
used, have been proposed to be associated with inflammatory activation (131). 
Which pathophysiological processes might be involved in an association of the 
inflammatory activation and IIH development need to be further investigated. 
5.3.2 Androgen hypotheses
A common denominator to some of the risk factors previously associated with 
IIH are also associated with changes in androgen levels, which has been proposed 
as a risk for IIH development (see background). Factors that can be coupled to 
androgen levels are: PCOS (associated with an excess androgen state in women), 
androgen treatments, tetracyclines that are often used to treat acne (acne being 
associated with hyperandrogenism (132)) and vitamin A treatments used to treat 
acne (however not prevalent enough for us to study). The proposed mechanism in 
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association to IIH is low levels in men and high levels in women (67). Our results 
supported this hypothesis in that we saw a tendency towards higher OR in ovary 
dysfunction and androgen treatments (significant compared to GP controls but only 
a tendency compared to obese controls). However, as the number of exposed cases 
and controls is low this renders large confidence intervals and a large uncertainty. 
Results from other studies support our findings, i.e. that testosterone deficiency 
was more prevalent in men with IIH than in controls (61), that PCOS was shown 
to be more prevalent in IIH women (69, 133), and that hyperandrogenism is asso-
ciated with earlier onset of IIH in women (71). Therefore, we believe our results 
could give further support to the androgen hypothesis.
5.3.3 Arterial hypertension and intracranial pressure regulation
Our results confirm the findings in prior minor case-control studies where arterial 
hypertension was more frequently seen compared to controls (60, 62). It is also 
reported to be a common comorbidity in IIH patients over 40 years of age (128). 
The descriptive study I revealed that arterial hypertension was a common comor-
bidity, especially among men, where 42% had this comorbidity compared to only 
8% of the women. In study IV, arterial hypertension stood out with an ORadjusted as 
high as 17.5 (10.5-29.3) compared to GP controls and 5.1 (3.6-7.3) compared to 
obese controls. An increased risk of development of new cardiovascular events 
and arterial hypertension has also been described after diagnosis of IIH compared 
to matched controls (also BMI matched) (134). 
Previous discussions have rendered that arterial hypertension is a confounder of 
known risk factors such as obesity, but our results also implicate that it might be 
a risk factor per se for IIH develop ment. Supposing this to be true, other risk fac-
tors associated with IIH such as SLE and kidney failure known to cause increased 
arterial blood pressure could trigger IIH disorder by means of blood pressure. A 
potential pathophysiological hypothesis could be through intracranial pressure 
regulatory mechanisms. There is some experimental evidence of a correlation 
between raised ICP and raised blood pressure by means of sympathetic activity 
(135). Other pathophysiological mechanisms involved in ICP regulations seems 
to be stenosis of the transverse venous sinus (136) that could also be involved in 
mechanisms keeping the cerebral perfusion stable. Sinus transversus stenosis is 
something we know to be common in IIH patients (7). Further studies are needed to 
address whether arterial hypertension is a risk factor involved in IIH development. 
5.3.4 Oral contraceptives and pregnancy
As IIH is so strongly associated with females of reproductive age, using contra-
ceptives and becoming pregnant is something that often needs to be considered 
during patient/physician consultations. Our results showed no increased risk of 
38
hormonal contraceptives and that exposure to pregnancy is not a risk factor for 
IIH development. This is consistent with recent studies and opinions (63, 137) 
but important to be verified in a large-scale study. Regarding pregnancy of course 
some might still develop or have the disorder while going through a pregnancy 
and thereby will need follow-up and treatment considerations. For women having 
had IIH prior to a pregnancy it is important they are provided with dietary advice 
and regular weight controls to avoid additional weight gain that increases the risk 
of recurrence/worsening of IIH (137).
5.3.5 Pharmacological risk factors
As described above, the proposed risk factors in study IV that showed significant 
association to IIH, need to be further investigated to determine whether it is the 
underlying condition for the treatments or the treatment itself that is the major risk 
in driving the development of IIH. This type of knowledge will be of importance 
in guiding the clinician on whether a specific treatment should be changed or if it 
is the underlying condition that needs to be treated. 
A recent review article addressing drug-induced intracranial hypertension (DIIH) 
analyzed this using the following proposed criteria (138): 
The patient meets the diagnostic criteria for IIH and at least four of the following: 
A. Signs or symptoms of increased ICP are not due to any pre-existing clinical 
condition
B. Signs or symptoms of increased ICP developed within a reasonable time interval 
of drug administration
C. Upon discontinuation of suspected drug, signs or symptoms of increased ICP 
improved after five half-lives with subsequent resolution 
D. Signs or symptoms of increased ICP recurred on re-challenge of suspected 
drug 
E. The suspected drug has been previously reported to be associated with increased 
ICP
The conclusion from this review using these criteria was that some drugs such as 
vitamin A derivatives, tetracyclines, recombinant growth hormone, and lithium 
treatments were the most strongly associated drugs with a direct drug-induced 
effect while the association with corticosteroids was moderate and quinolones, 
oral contraceptives and several others were weakly associated with IIH (138). 
This is consistent with our results, particularly increased OR for lithium and 
tetracyclines. Regarding the antibiotics all of our studied antibiotic groups had 
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significantly increased OR for exposure the year prior to index date compared to 
controls, but to a higher extent in tetracyclines (IIH vs GP OR = 3.6 (2.6-4.8)) with 
almost significant (only slightly overlapping) difference in confidence intervals 
 compared to the total antibiotic treatment group (IIH vs GP OR= 2.2 (1.9–2.7)). 
This was also the case when analyzing the sulpha antibiotic exposure group, but 
CIs were wider due to less frequent usage, so these results should be interpreted 
with some uncertainty. We believe that the reason that antibiotics as a group all have 
higher OR could be explained by the inflammatory hypothesis with the underlying 
infectious disorder/inflammation as a main driving mechanism. However, since 
the tetra cyclines have even higher OR than all antibiotics combined this could 
implicate also a specific drug-induced effect. The same mechanism could apply to 
corticosteroidal use but as OR were moderately increased its hard to say whether 
it supports a specific drug-induced action. Therefore, our results suggest a drug 
specific effect by tetracyclines and lithium and possibly to some extent also by 
sulpha drugs and corticosteroidal drugs. 
It is important to know how certain drugs function to impose specific patho-
physiological effects associated with increased ICP and this needs to be further 
evaluated. Some hypotheses have been proposed over the years. One hypothesis 
discussed in the literature is that some treatments associated with IIH such as 
cortico steroids and vitamin A might upregulate the expression of AQP1 (139, 140).
5.4 Strengths and limitations
5.4.1 Register studies
Sweden’s unique national registers make it possible to collect data on a national 
level, which can provide a decent sized sample even when investigating rare dis-
eases. The source population studied the year 2000 was 6,945,013 individuals and 
increased over the study period to 7,918,746 in the year 2016 (population over 
18 years of age at the end of December the particular year). When performing 
 studies on the whole population and a population with this magnitude the risk of 
a selection bias by including a certain group with certain characteristics is thereby 
considered to be low. 
IIH patients will have contact with specialized care when receiving their diagnosis 
and therefore we think that the majority of IIH patients should be captured in the 
Swedish NPR register. An additional strength is that the controls used in study III 
and IV came from the same population and were matched with the cases according 
to region of residence as well as age and sex to control for confounding. 
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5.4.2 Available information in retrospective studies
There are several limitations when doing retrospective register studies. Firstly, the 
data are collected prior to the study start meaning that we may lack information on 
potentially important variables/factors. In this case there was no information on 
BMI (height or weight) available in Swedish registries which is of great importance 
when investigating a disorder like IIH which is so strongly associated with obesity. 
Other data such as smoking status and alcohol consumption could have been use-
ful in the adjusted model, but these data are not available in any of the national 
Swedish registers. 
Lack of clinical data of importance was a clear problem also in study I when looking 
retrospectively in medical records. Many times, useful parameters such as precise 
weight and height (BMI), a precise descriptive eye status, smoking status and so 
forth were missing, and we had to rely on terms such as overweight, normal eye 
status or papilledema. This problem became more evident in those IIH cases in 
study I with a code for IIH during the study time-period that were prevalent cases. 
Many of those had received their first diagnosis many years earlier, which meant 
we were unable to get firsthand information from case records at the time of diag-
nosis. Therefore, the diagnosis had to be evaluated from data found in more recent 
reports, resulting in many of these patients receiving a probable IIH diagnosis. 
5.4.3 Use of obese controls in study III and IV
When evaluating risk factors in a disorder such as IIH with close association to 
obesity we knew that this was an important variable to consider. Unfortunately, 
BMI is not recorded in any national registers apart from MBR. We were there-
fore not able to include this parameter when matching cases with controls. To 
overcome this major limitation, we included a second control group having had 
a recorded ICD-10-SE code of obesity diagnosis registered in NPR. This was of 
great importance to the study to be able to evaluate the data comparing also to a 
control group being obese. However, receiving an obesity diagnosis in the NPR is 
uncommon and probably only represents patients that are severely obese and seek 
medical attention because of their obesity or its complications. This could mean 
that the groups are not entirely similar with respect to BMI and comorbidities if 
the obese controls are more severely obese than the IIH patients and thereby have 
a more complex health situation even though they are age and sex matched. The 
same can apply to the GP controls in that we believe this group to be less obese 
than the IIH cases. Therefore, we believe it was important to display results both 
for comparison with GP controls and obese controls. We believe that the “true 
results” if it would have been possible to obtain BMI matched controls probably 
would be somewhere in between. 
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5.4.4 Validity of registers
An additional strength to our register studies (study III and IV) is that prior to this 
we did a validation study (study I) looking at how valid the IIH diagnosis was 
in the NPR and then proceeded with constructing and testing algorithms (study 
II) to better predict “true IIH cases” from the NPR diagnosis. In study I, only 
65% had a correct diagnosis code according to established diagnostic criteria. To 
overcome this limitation, we made the algorithms (study II) that better predicted 
which patients to include in register studies as correct IIH cases. However, this is 
still only a prediction and incorrect IIH cases will to some extent be included and 
there are probably also IIH cases which fulfil diagnosis criteria that our algorithms 
have identified as likely not IIH and therefore is not included in the analysis. We 
do however believe this is the best way to do register studies and the only way to 
perform large scale studies on such a rare disorder which is often misdiagnosed. 
Limitations with validity of registered diagnosis codes might apply to the expo-
sures that we are investigating in study III and IV. The validity of register data on 
specific diagnosis codes is often not done, but overall validity is considered good. 
Some misclassification bias of exposure codes is to be expected but we believe 
this to be non-differential, i.e. this happens randomly and is expected to affect 
cases and controls similarly. 
The validity of the PDR is very good since it is an automatized system record-
ing all prescriptions and their dispensing from pharmacies. However, we lack the 
information on whether patients actually were taking the drug. 
The MBR is very good with coverage of 97-99% of all births in Sweden (121). 
5.4.5 Surveillance and selection bias
We cannot rule out that IIH cases due to their symptoms might have been more 
prone to seek help from specialized healthcare than GP’s resulting in surveillance 
bias. Physicians might have done investigations resulting in diagnosis of concomi-
tant disorders that might otherwise have been undetected. Consequently, chronic 
or uncomplicated disorders that usually are diagnosed and treated in primary care, 
might have been coded in specialized care more often in IIH cases than in controls. 
As a sensitivity analysis, we therefore investigated the ICD-10-SE codes for such 
disorders as a primary analysis and as a secondary analysis looked at the drug 
dispensing on drugs used to treat these same disorders to investigate if we would 
get corresponding results. The purpose of this was also to overcome the limita-
tion that the NPR does not contain data on diagnoses from primary care contacts. 
In study III we did sensitivity analysis looking at the number of codes for infec-
tious and inflammatory disorders during three-month intervals the year prior to 
42
diagnosis to see if our results were due only to surveillance bias. We found higher 
OR in the period closest to diagnosis but otherwise stable and increased OR over 
the investigated 3-month periods. We believe that this could be due to surveil-
lance bias, but we cannot rule out that a recent inflammatory activation pushes 
the patient to worsening of symptoms and therefore subsequent diagnosis of IIH.
We suspect that the obese control group could be more severely obese compared to 
IIH cases as this is a rare diagnosis in the registries. This might make them more 
prone to other health problems and could result in a selection bias with the obese 
control group possibly being sicker compared to IIH patients. 
5.4.6 Limitations with the algorithms
When validating the algorithms produced in study II we found that these algo-
rithms were poor predictors of sIH. In our cohort in study I, 8% of patients had a 
validated diagnosis of sIH and they often had similar symptoms as IIH patients, 
many with longstanding need for ICP lowering treatments and several follow-ups. 
In fact, there is no unique code for sIH in ICD-10-SE, making G93.2 the best choice 
for clinicians for follow-up visits when the underlying cause is treated and no longer 
present. This points to a limitation of the ICD-10-SE code system; however, this 
will be possible to code in the new coming ICD-11 coding system. It would have 
been useful to know if these sIH patients also had a registered diagnosis code for 
the primary cause in close relationship with the IIH diagnosis code, but we did not 
have that data available as we only received information on code G93.2 in study I. 
Another factor that might have improved the algorithms would have been the code 
for papilledema (H47.1) – but we did not have that data and can only speculate to 
what extent that might or might not have affected the validity of the algorithms. 
5.5 Generalizability
The results in study I describe an IIH cohort in one county dominated by a big city 
and its suburbs. This might affect generalizability and results might have looked 
different in another setting. However, study III and IV are national population 
studies and we therefore believe that results could apply to other similar popula-
tions. Regarding risk factor analyses we believe this could apply to other western 
counties with a similar range of comorbid disorders. The difference in obesity 
prevalence between countries, however, is likely to affect the degree of exposure 
to obesity related risk factors and IIH incidence.
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6 CONCLUSIONS
These studies add new input to the research field of the IIH disorder:
Study I: 
• Our validation study showed that the diagnosis code for IIH in NPR was incor-
rect in 35% of the cases, mostly due to patients not fulfilling the diagnostic 
criteria. Thus, when planning for register based studies of IIH or any other 
disorder, it is of utmost importance to evaluate the validity of a registered 
diagnosis by cross checking with data from an adequate number of case records. 
• The incidence of IIH in Sweden is in the lower range compared to what is 
reported in recent studies in northern Europe.
• In the case records obesity/overweight was reported in 92% of the true IIH 
cases, and in 61% of the patients for whom BMI was recorded the mean BMI 
was 34.7. These findings are in line with other studies indicating that obesity is 
likely to be part of the pathophysiological process or an important risk factor. 
Study II: 
• We found that construction and testing algorithms was a good tool to better 
predict which cases to include in register studies on IIH. We found that patients 
having had several visits with the same diagnosis code improved the diagnostic 
prediction. 
Study III and IV: 
• The incidence of IIH was shown to be rising in Sweden, and this also seems 
to be related to the reported increase of obesity prevalence in Sweden and in 
other countries. As obesity is a major risk factor for IIH, body weight needs 
to be closely monitored in these patients. On a national level it is important to 
use health resources wisely to prevent comorbidities and health problems that 
are associated with obesity, IIH being one of them. 
• Our two case-control studies on risk factors increase the evidence that there 
are associations between IIH and infectious/inflammatory conditions and other 
previously suspected risk factors such as arterial hypertension, SLE, kidney 
failure, PCOS that can not only be explained by obesity. 
• Associations with tetracyclines, lithium and corticosteroids exposures were 
also evident. 
• Anticonception and pregnancy – did not show association to IIH development. 
• Altogether, our findings give support for a multifactorial pathogenesis of IIH.
• We discuss our results in relation to 3 hypotheses on possible pathophysi-
ological mechanisms that could be involved in IIH development: inflammatory 
hypothesis, androgen hypothesis and the hypothesis of disturbed ICP regulatory 
mechanisms. Further studies are necessary to address these hypotheses. 
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7 FUTURE PERSPECTIVES
IIH is a disorder affecting primarily obese females of reproductive age, and often 
give rise to longstanding symptoms and a potential risk for irreversible visual 
deficits. Our studies show that the incidence is increasing and as we know that 
IIH has a large impact on patients’ quality of life and gives rise to substantial costs 
for the society – it is important to continue the efforts to better treat and help this 
patient group. 
Our findings also support the theory that the disorder has a multifactorial origin 
and accordingly needs to be individualized. Epidemiological studies help us show 
associations and develop hypotheses but cannot explain the pathophysiological 
and causal relationships. Considering this, other studies are needed to improve 
 knowledge on the pathophysiological level. As well as evidence-based knowledge 
on best treatment and healthcare regime for this patient group, both on an individual 
level as well as structural levels (chain of structured healthcare actors). The most 
important research areas in the future are:
7.1 Understanding pathophysiology
To understand the pathophysiological processes behind what causes the increased 
ICP development in IIH and which pathophysiological processes are involved 
are of great importance. Today several studies in IIH have been performed and 
knowledge is being continually generated. I believe more studies looking into how 
inflammatory activation could be involved in IIH development would be interesting 
to perform. Also, what precise mechanisms could be involved that could explain 
an increasing risk of IIH if exposed to for example lithium and tetracyclines. With 
greater knowledge on the pathophysiological mechanisms we might improve pre-
ventative initiatives to lower disease prevalence. This could improve treatments 
in use today but also develop new more specific treatments. This would also help 
us better guide our patients in risk factor managements and treatment choices. 
7.2 Treatment for IIH 
I see a need for more randomized comparison studies regarding treatments to 
provide evidence-based guidelines for IIH treatment to provide guidance for 
clinicians in handling this quite complex patient group. Studies are ongoing on 
new treatments as well as comparative studies on treatments already in use today, 
so hopefully we have better evidence and better treatments to offer our patients 
in the future. Working with this patient group and during my research studies I 
have gained a greater understanding of the complexity of this disorder, its likely 
multifactorial pathogenesis and that we most certainly will continue to need indi-
vidually adjusted treatment regimes.
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7.3 Quality of life, headache and cognitive function 
After normalization of ICP some IIH patients continue having complex problems 
with headache, fatigue, concentration and possibly impaired cognitive function 
which reduce their quality of life and affect work performance. There are only 
a few studies on these aspects. The outcome of IIH in the long perspective is 
sparsely known. These factors need to be more investigated in the future. This is 
of importance to guide patients and health providers on how to best use our health 




Idiopatisk intrakraniell hypertension (IIH) är en relativt ovanlig sjukdom som ffa 
drabbar unga överviktiga kvinnor. Vi vet väldigt lite om vad det är som orsakar 
IIH, därav namnet idiopatisk. Sjukdomen kännetecknas av högt intrakraniellt 
tryck som i sin tur ofta orsakar symtom som huvudvärk, synpåverkan, illa mående 
och pulserande ljud i öronen. Många gånger är symtomen långvariga, kräver 
många kontroller inom sjukvården och höga doser trycksänkande läkemedel med 
besvärande biverkningar. Det finns också flera studier som visar på risk att dessa 
patienter drabbas av permanent synskada och kronisk huvudvärksproblematik, 
men också att de kanske får påverkan på sk kognitiva funktioner som minne och 
processhastighet. 
För att kunna utveckla bättre behandlingar krävs ofta att man vet de bakom liggande 
mekanismerna till sjukdomen. Idag vet vi att det finns en stark association mellan 
IIH och exempelvis kvinnligt kön, fertil ålder och övervikt. Men frågorna varför 
och hur har vi inte besvarat. Långt ifrån alla överviktiga kvinnor drabbas ju av 
denna sjukdom. 
Syftet med denna avhandling var att bättre kartlägga sjukdomsförekomsten i 
Sverige och de faktorer som verkar öka risken att insjukna i sjukdomen. Varför 
är detta intressant? För det första kan en kartläggning av sjukdomens incidens 
och samsjuklighet ge oss kunskap om hur mycket ohälsa sjukdomen skapar (hur 
många drabbas, ökning eller minskning av sjukdomsförekomst, vilka drabbas pri-
märt och hur ser dessa ut gällande sin hälsosituation). Man kan också utifrån detta 
i ett längre perspektiv dra slutsatser kring kostnader, behov av vårdresurser osv. 
Vi fann att incidensen av IIH i Stockholms län under 2006–2013 var 0,65 per 
100 000 personer över 18 år. Sjukdomen var sex gånger vanligare hos kvinnor 
och majoriteten av dessa var överviktiga. I den större registerstudien var medel-
incidensen i stort sett densamma 0,71 per 100 000 men jämför man över hela 
perioden så ses en stadig och tydlig ökning som vi bedömer sannolikt beror på 
den rapporterade ökningen av fetma i världen och i Sverige. 
Det vi fann i studie I var att många patienter (hela 35%) som fått diagnoskoden för 
IIH inte uppfyllde diagnoskriterierna. För att kunna genomföra registerstudier var 
vi därför tvungna att hitta en metod som med större sannolikhet kunde identifiera 
rätt patienter att undersöka. Utifrån materialet i studie I skapade vi algoritmer 
(statistisk metod) som genom att använda faktorer som ålder, att man fått diagnos-
koden flera gånger samt i den ena av algoritmerna även läkemedel som används 
för behandling av sjukdomen (Diamox® = acetazolamid) ökade sannolikheten för 
att vi inkluderade rätt personer, dvs patienter med IIH. 
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Vidare ville vi studera om IIH patienterna var mer exponerade för vissa misstänkt 
utlösande faktorer före utvecklingen av IIH jämfört med matchade kontroller. Vi 
tittade bland annat på faktorer som man tidigare misstänkts varit associerade med 
sjukdomen. Vi använder oss av våra stora svenska register. Detta innebär att vi 
kan studera misstänkta utlösande faktorer i en mycket större grupp patienter (IIH 
fall) och kontroller än vad man tidigare kunnat göra. Totalt inkluderade vi 902 
fall och 4510 kontroller från befolkningen matchade på ålder, kön och bostadsort 
och lika många matchade personer som även hade en fetmadiagnos. I den del 
där vi tittade på läkemedelsuttag från apotek inkluderades 654 IIH fall och 3270 
matchade kontroller i båda kontrollgrupperna. 
Vi fokuserade på om infektion och inflammation var associerat till ökad risk för att 
insjukna i IIH och fann att risken var 3–4 gånger större att man hade varit expone-
rad för dessa sjukdomstillstånd året innan man fick sin IIH diagnos bekräftad. Vi 
tittade också på de tidigare föreslagna riskfaktorerna njursvikt, inflammatoriska 
sjukdomen SLE, polycystiskt ovariesyndrom, samt högt blodtryck. Våra resultat 
bekräftade att dessa tillstånd verkar öka risken att utveckla IIH. Likaså förefaller 
behandling med vissa läkemedel som tetracycliner, litium och kortisonanvändning 
vara betydligt vanligare hos IIH patienter året innan sjukdomsdebut jämfört med 
kontrollgrupperna. Intressant var också att vår studie bekräftade att graviditet och 
p-pilleranvändning inte verkar vara en riskfaktor för IIH utveckling. 
Fortfarande är de bakomliggande mekanismerna för dessa riskökningar inte klarlagd 
men vi presenterar hypoteserna att 1.) inflammation kan vara en viktig gemensam 
pusselbit, 2.) hormonella förändringar i androgenregleringen och 3.) faktorer som 
påverkar den intrakraniella tryckkontrollen kan vara av betydelse för utvecklingen 
av IIH sjukdomen. Dessa teorier behöver vara fokus för framtida studier när det 
gäller IIH sjukdomen och dess mekanismer med förhoppning om att kunna ge 
mer kunskap och nyare och bättre behandlingar för denna drabbade patientgrupp. 
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9 APPENDIX
9.1 ICD-10-SE codes and ATC codes used for Analyses 
study III
ICD-10-SE codes used for the analyses:
All infectious and inflammatory disorders: All A+B diagnosis, J00-22, L00-08, N10, N12, 
N70-71, K35, K81, K85, M00-03, J40-46, N00-
01, N03, N05, N11, M05-14, M30-36, K50-52, 
K90, L20-30
Infectious disorders: All A+B diagnosis, J00-22, L00-08, N10, N12, 
N70-71, K35, K81, K85, M00-03
Inflammatory disorders: J40-46, N00-01, N03, N05, N11, M05-14, M30-
36, K50-52, K90, L20-30
Specific infections: A + B diagnoses
Respiratory inflammation/infections: J00-22, J40-46
Kidney inflammation/infections: N00-01, N03, N05, N10-12
Female genital inflammation/infections: N70-77
Systemic inflammatory disorder: M30-36, M05-14
GI inflammation/infections: K20, K29, K50-52, K35-37, K61, K73, K75, K80-
81, K85, K90
Skin inflammation/infections: L00-08, L20-30
ATC codes used for the analyses:
Antibiotic+antiviral treatments: J01, J05, D06, P
Antibiotic treatments: J01
Systemic corticosteroids: H02
Non-steroidal antiinflammatory drugs: M01
GI drugs: A07
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9.2 ICD-10-SE codes and ATC codes used for Analyses 
study IV
ICD-10-SE codes used for the analyses:
Addison’s disorder E27
Arterial hypertension I10-15







Ovary dysfunction incl PCOS in females E28
Sarcoidosis D86
SLE M32
Turner and Downs syndrome Q96+Q90
ATC codes used for the analyses:
Androgen treatments G03B
Antihypertensive treatments C02-03, C07-09
Hormonal contraceptives (systemic use) G03A
Iron anemia treatments B03A
Lithium N05AN
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